BioCentury | May 5, 2016
Distillery Therapeutics

Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)

...Next steps could include testing anti-GD3 antibodies or ST8SIA1 inhibitors in additional models of glioblastoma. Life Science Pharmaceuticals Inc....
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

...a cell surface antigen expressed on 90% of melanoma cells. KHK licensed it to Life Science Pharmaceuticals Inc....
...Ltd. (Tokyo:4151), Tokyo, Japan La Jolla Institute for Allergy & Immunology , La Jolla, Calif. Life Science Pharmaceuticals Inc....
...Asia KW-2871 (A) Chimeric antibody that targets GD3 ganglioside Metastatic melanoma Ph II in U.S. Life Science Pharmaceuticals Inc....
BioCentury | Dec 20, 2010
Clinical News

ABT-806: Phase I started

...to the compound from Life Science under a 2008 deal (see BioCentury, Nov. 24, 2008). Life Science Pharmaceuticals Inc....
BioCentury | Nov 18, 2010
Distillery Therapeutics

Indication: Cancer

...microenvironment. Next steps include identifying a way to target FAP-expressing cells in the tumor microenvironment. Life Science Pharmaceuticals Inc.'s...
BioCentury | Nov 24, 2008
Company News

Life Science Pharmaceuticals, Abbott deal

...completed Phase I testing to treat solid tumors last year. Financial terms were not disclosed. Life Science Pharmaceuticals Inc....
BioCentury | Mar 19, 2007
Company News

Life Science Pharmaceuticals, Kyowa Hakko Kogyo Co. Ltd. deal

...3Q07. Kyowa will receive an undisclosed upfront payment and is eligible for milestones and royalties. Life Science Pharmaceuticals Inc....
BioCentury | Mar 16, 2007
Company News

Life Science in-licenses Kyowa's KW-2871

...Kyowa Hakko Kogyo (Tokyo:4151) granted Life Science Pharmaceuticals (Greenwich, Conn.) exclusive worldwide rights to develop and market KW-2871...
BioCentury | Mar 12, 2007
Clinical News

Ch806: Phase I data

...were well tolerated. Data were published in the Proceedings of the National Academy of Sciences. Life Science Pharmaceuticals Inc....
BioCentury | Feb 19, 2007
Company News

American Life Science Pharmaceuticals Inc. management update

...American Life Science Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Hired: Michael Pierschbacher as president, CEO and a...
BioCentury | Jun 5, 2006
Company News

Life Science Pharmaceuticals, Ludwig Institute for Cancer Research deal

...factor receptor (EGFR) , fibroblast activating protein, and an undisclosed epitope involved in colorectal cancer. Life Science Pharmaceuticals Inc....
Items per page:
1 - 10 of 11
BioCentury | May 5, 2016
Distillery Therapeutics

Therapeutics: GD3 ganglioside; ST8 α-N-acetyl-neuraminide α-2,8-sialyltransferase 1 (ST8SIA1); prominin 1 (PROM1; CD133)

...Next steps could include testing anti-GD3 antibodies or ST8SIA1 inhibitors in additional models of glioblastoma. Life Science Pharmaceuticals Inc....
BioCentury | Mar 18, 2013
Strategy

Japan's biggest biotech

...a cell surface antigen expressed on 90% of melanoma cells. KHK licensed it to Life Science Pharmaceuticals Inc....
...Ltd. (Tokyo:4151), Tokyo, Japan La Jolla Institute for Allergy & Immunology , La Jolla, Calif. Life Science Pharmaceuticals Inc....
...Asia KW-2871 (A) Chimeric antibody that targets GD3 ganglioside Metastatic melanoma Ph II in U.S. Life Science Pharmaceuticals Inc....
BioCentury | Dec 20, 2010
Clinical News

ABT-806: Phase I started

...to the compound from Life Science under a 2008 deal (see BioCentury, Nov. 24, 2008). Life Science Pharmaceuticals Inc....
BioCentury | Nov 18, 2010
Distillery Therapeutics

Indication: Cancer

...microenvironment. Next steps include identifying a way to target FAP-expressing cells in the tumor microenvironment. Life Science Pharmaceuticals Inc.'s...
BioCentury | Nov 24, 2008
Company News

Life Science Pharmaceuticals, Abbott deal

...completed Phase I testing to treat solid tumors last year. Financial terms were not disclosed. Life Science Pharmaceuticals Inc....
BioCentury | Mar 19, 2007
Company News

Life Science Pharmaceuticals, Kyowa Hakko Kogyo Co. Ltd. deal

...3Q07. Kyowa will receive an undisclosed upfront payment and is eligible for milestones and royalties. Life Science Pharmaceuticals Inc....
BioCentury | Mar 16, 2007
Company News

Life Science in-licenses Kyowa's KW-2871

...Kyowa Hakko Kogyo (Tokyo:4151) granted Life Science Pharmaceuticals (Greenwich, Conn.) exclusive worldwide rights to develop and market KW-2871...
BioCentury | Mar 12, 2007
Clinical News

Ch806: Phase I data

...were well tolerated. Data were published in the Proceedings of the National Academy of Sciences. Life Science Pharmaceuticals Inc....
BioCentury | Feb 19, 2007
Company News

American Life Science Pharmaceuticals Inc. management update

...American Life Science Pharmaceuticals Inc. , San Diego, Calif. Business: Neurology Hired: Michael Pierschbacher as president, CEO and a...
BioCentury | Jun 5, 2006
Company News

Life Science Pharmaceuticals, Ludwig Institute for Cancer Research deal

...factor receptor (EGFR) , fibroblast activating protein, and an undisclosed epitope involved in colorectal cancer. Life Science Pharmaceuticals Inc....
Items per page:
1 - 10 of 11